Can You Get Pregnant on Ozempic? Fertility, PCOS, and What Patients Often Underestimate

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Ozempic does not prevent pregnancy. Weight loss can restore ovulation, especially in PCOS patients, which can increase pregnancy probability.
• Subcutaneous semaglutide has not shown a clinically meaningful interaction with oral contraceptive absorption; oral semaglutide (Rybelsus) has specific manufacturer guidance.
• Patients trying to conceive should discontinue at least 2 months before active attempts.
• PCOS patients commonly experience improved menstrual regularity and ovulation with even modest weight loss.
• Contraception planning should include consideration of restored fertility during weight loss.

Direct answer

Yes, you can get pregnant on Ozempic. The medication is not a contraceptive, and weight loss frequently restores ovulation in patients whose cycles were disrupted by obesity or PCOS. If you want to avoid pregnancy, use a reliable contraceptive method. If you want to conceive, plan a 2-month discontinuation window before active attempts. If you are pregnant, planning pregnancy, or breastfeeding, do not start, continue, or stop GLP-1 medications without OB-GYN sign-off.

Table of contents

1. Why fertility can improve during semaglutide treatment
2. The PCOS picture in detail
3. Ozempic and oral contraceptive absorption
4. Contraceptive options during weight loss
5. How long to wait before conception attempts
6. What to know about restored ovulation timing
7. Fertility treatment combinations
8. Male fertility on GLP-1 medications
9. Pre-pregnancy planning checklist
10. The contrary view: semaglutide as a fertility aid
11. FAQ
12. Sources

Why fertility can improve during semaglutide treatment

Obesity is a common driver of anovulatory cycles. Excess adipose tissue increases peripheral conversion of androgens to estrogens, which disrupts the hypothalamic-pituitary-ovarian axis. Insulin resistance, often co-occurring with obesity, further disrupts ovulation in women with PCOS. Weight loss reverses these mechanisms in many patients, with 5 to 10 percent weight loss often sufficient to restore regular cycles.

Semaglutide produces this kind of weight loss in many patients. STEP 1 reported a mean weight loss of approximately 14.9 percent over 68 weeks. For a patient who was previously anovulatory, that magnitude of loss frequently shifts the menstrual pattern.

The functional consequence: women who were not getting pregnant despite trying may begin ovulating during semaglutide treatment. Women who were using less reliable contraception (calendar tracking, withdrawal) may face increased pregnancy risk because of newly regular ovulation.

The PCOS picture in detail

Polycystic ovary syndrome affects an estimated 6 to 12 percent of reproductive-age women. Hallmarks include irregular menses, hyperandrogenism, and polycystic ovarian morphology. Obesity is present in roughly half of patients with PCOS in most populations.

Weight-based therapy is first-line for PCOS-related infertility according to most reproductive endocrinology guidelines. A 2023 randomized trial in Diabetes, Obesity and Metabolism evaluated semaglutide in patients with PCOS and obesity; the treatment arm showed greater weight loss and improved menstrual regularity compared to placebo. These data do not establish semaglutide as a fertility treatment, but they support the mechanism by which weight loss restores ovulation in PCOS.

Patients with PCOS who are not actively trying to conceive should pay particular attention to contraception during semaglutide treatment. The same patient who could not conceive at baseline may ovulate predictably after several months of weight loss.

Ozempic and oral contraceptive absorption

GLP-1 receptor agonists delay gastric emptying. This raises a theoretical question about the absorption of orally administered medications, including combined oral contraceptives.

For subcutaneous semaglutide (Ozempic, Wegovy), pharmacokinetic studies have not demonstrated a clinically meaningful effect on oral contraceptive absorption. The Ozempic label does not currently recommend additional contraceptive measures based on absorption interaction.

For oral semaglutide (Rybelsus, used in type 2 diabetes), the manufacturer recommends that patients on oral medications with narrow therapeutic index or absorption sensitivity discuss with their prescriber. The same general principle applies.

The cleaner approach for many patients on any GLP-1 medication is a non-oral contraceptive method (IUD, implant, depot injection), which removes the absorption question entirely. This is a discussion to have with your prescriber and OB-GYN.

Contraceptive options during weight loss

Method	Typical-use failure rate per year	Notes on GLP-1 coexistence
Copper IUD	About 0.8 percent	Not affected by GLP-1 absorption considerations
Hormonal IUD	About 0.1 to 0.4 percent	Not affected by GLP-1 absorption considerations
Subdermal implant	About 0.1 percent	Not affected by GLP-1 absorption considerations
Depot medroxyprogesterone (injectable)	About 4 percent	Some patients note weight changes with this method; coordinate with weight-loss plan
Combined oral contraceptive	About 7 percent (typical use)	Subcutaneous semaglutide: no specific additional precaution. Oral semaglutide: discuss with prescriber.
Progestin-only pill	About 7 percent (typical use)	Same considerations as combined OCP
Barrier methods	About 13 to 21 percent	Higher failure rates make these a poorer match for patients whose fertility may be restored on GLP-1 treatment

How long to wait before conception attempts

Novo Nordisk recommends discontinuing semaglutide at least 2 months before a planned pregnancy. The pharmacokinetic basis: semaglutide half-life is about 1 week, near-complete clearance takes about 5 weeks, and the additional buffer allows for individual variability and establishment of alternative care plans.

For PCOS patients, the discontinuation window can also serve another purpose: ovulation patterns may stabilize once the gastric-emptying effect of the medication is gone. Some reproductive endocrinologists prefer to observe at least one or two cycles off medication before active attempts.

What to know about restored ovulation timing

Ovulation may resume well before a patient reaches her target weight. For PCOS patients with anovulatory baseline, weight loss of 5 to 10 percent often triggers ovulation. This can happen within the first 3 to 6 months of GLP-1 treatment.

The clinical implication: if you started semaglutide while having irregular cycles and assumed pregnancy was unlikely, that assumption may stop being true at some point during treatment. Patients who do not want pregnancy should adjust contraception planning accordingly, ideally before starting semaglutide.

Fertility treatment combinations

If you are receiving fertility treatment (clomiphene, letrozole, gonadotropins, IVF) while on semaglutide, the coordination question becomes important. Most reproductive endocrinologists prefer that patients discontinue semaglutide before active fertility treatment cycles, mirroring the pre-pregnancy washout principle.

For weight-related infertility without other diagnoses, weight loss alone may resolve the issue. For combined diagnoses (PCOS plus advanced maternal age, for example), discussion with reproductive endocrinology about timing is important.

Male fertility on GLP-1 medications

Animal studies in male semaglutide exposure did not identify teratogenicity from paternal exposure. Weight loss in men can improve sperm parameters in obesity-related subfertility; this is a general weight-loss effect rather than a medication-specific effect.

There is no formal recommendation for male partners to discontinue semaglutide during conception attempts. If you have specific concerns or unexplained subfertility, an evaluation including semen analysis and discussion with reproductive endocrinology is appropriate.

Pre-pregnancy planning checklist

• Discuss conception plans with your prescriber and OB-GYN well in advance.
• Establish a discontinuation date at least 2 months before active attempts.
• Begin a prenatal vitamin with at least 400 mcg folic acid at discontinuation.
• Review your contraception plan during the pre-pregnancy weight-loss period to avoid inadvertent conception while still on medication.
• Optimize underlying conditions (A1c if diabetic, blood pressure, thyroid).
• Schedule a pre-pregnancy visit for personalized counseling.

The contrary view: semaglutide as a fertility aid

Some patients and clinicians describe semaglutide as a de facto fertility aid for women with PCOS or obesity-related infertility. The argument: weight loss restores ovulation, the medication produces effective weight loss, therefore the medication enables conception that would not otherwise occur.

This framing is partially accurate but importantly incomplete. The medication enables weight loss that enables ovulation. The medication itself is not a fertility treatment, has not been approved for that indication, and carries pregnancy precautions that constrain its use during active conception attempts.

The clean framing: semaglutide can be a step on the path to pregnancy by helping with pre-conception weight optimization. The medication should be discontinued before pregnancy attempts; pregnancy itself should occur off medication. This sequencing makes semaglutide useful in fertility planning even though it is not a fertility treatment.

Compounded medication note for this topic

For Can You Get Pregnant on Ozempic? Fertility, PCOS, and What Patients Often Underestimate, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Can you get pregnant on Ozempic? Yes. The medication is not contraceptive. Weight loss can restore ovulation.

Does Ozempic increase fertility? Indirectly, through weight loss. PCOS patients commonly see improved cycle regularity.

Does Ozempic affect birth control? Subcutaneous semaglutide: no clinically meaningful interaction with oral contraceptives. Oral semaglutide: discuss with prescriber.

How does Ozempic affect PCOS? Weight loss improves ovulation and cycle regularity. The medication is not FDA-approved for PCOS but is used off-label for weight management in this population.

Should I use contraception on Ozempic? Yes if you do not want pregnancy. Long-acting reversible methods are particularly reliable.

How long before trying to conceive should I stop Ozempic? At least 2 months.

Will my cycles become more regular on Ozempic? Often yes, particularly for PCOS or weight-related cycle irregularity.

Does Ozempic affect egg quality? Direct effects on oocyte quality are not characterized. Weight loss in general may improve oocyte quality in obesity-related infertility.

Can my partner take Ozempic while we try to conceive? No formal restriction. Animal data did not flag paternal teratogenicity.

What if I become pregnant before the 2-month washout? Stop the medication, contact your prescriber and OB-GYN, and consider pregnancy registry enrollment.

Sources

1. FDA. Ozempic (semaglutide) injection prescribing information. Use in Specific Populations.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. International PCOS Network. International evidence-based guideline for the assessment and management of polycystic ovary syndrome. 2023 update.
4. Carmina E et al. Polycystic Ovary Syndrome: Update on Pathogenesis and Treatment. Endocrine Reviews. Recent edition.
5. Trial of Semaglutide in Patients with PCOS. Diabetes, Obesity and Metabolism. 2023.
6. American Society for Reproductive Medicine. Practice committee opinion on obesity and reproduction.
7. Norman RJ et al. Improving reproductive performance in overweight and obese women with weight loss. Human Reproduction Update.
8. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. JCEM. 2015 with updates through 2024.
9. FDA. Rybelsus (oral semaglutide) prescribing information. Drug interactions.
10. ACOG Committee Opinion 731: Obesity in Pregnancy. 2018, reaffirmed.
11. Trussell J. Contraceptive failure in the United States. Contraception. 2011.
12. Novo Nordisk. Semaglutide Pregnancy Exposure Registry.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that links patients with independent licensed clinicians and U.S.-based pharmacies. Fertility planning is a clinical decision that involves you, your prescriber, OB-GYN, and (in some cases) a reproductive endocrinologist.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. Pre-pregnancy washout and pregnancy avoidance guidance applies with at least equal weight as for brand-name semaglutide.

Results Disclaimer. Fertility outcomes vary by age, comorbidities, ovarian reserve, baseline weight, and many other factors. Information in this article is general clinical context, not a personalized fertility plan.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.